Abstract:Background: Benzodiazepines have long held a leading position in medical therapeutics, known for their multiple common therapeutic properties and primarily being prescribed for anxiety and insomnia. However, their lack of specificity and various side effects have led to a reevaluation of their long-term use, resulting in a rapid growth in the literature focusing on targeted therapies. Areas of uncertainty: Despite many efforts, uncertainties persist and there are heterogeneous findings across studies regarding the pharmacological effects attributed to gamma-aminobutyric acid type A (GABAA) receptor subunits. Selective compounds targeting GABAA receptor alpha subunits are currently under active research and definitive conclusions have not been reached yet. Some compounds have not progressed to clinical trials, while others, if advanced, have been halted. These challenges emphasize the difficulty in translating preclinical findings into clinical use. Data sources: A literature review was conducted using the PubMed database, searching for articles discussing GABAA receptor subunits. The search was refined by including only selective compounds with potential anxiolytic and cognitive enhancement properties. Results: Findings reveal compounds with promising anxiolytic and antidepressant effects with minimal sedation and absence of tolerance development. Moreover, some compounds show potential in alleviating cognitive dysfunction. There is a broad spectrum of potential therapeutic applications for selective compounds, ranging from neurological disorders such as epilepsy and neuropathic pain to cognitive dysfunction-related conditions. Currently, the leading selective compounds with the most promising results in ongoing clinical trials are basmisanil and darigabat. Basmisanil holds further exploration potential in the treatment of cognitive impairment and related conditions, while darigabat shows progress in the advancement of adjunctive therapy of focal onset seizures and for the treatment of panic disorder, respectively. Conclusions: Future drug discovery efforts are encouraged to focus on positive allosteric modulators that selectively target the α2, α3 subunits and negative/positive allosteric modulators that target the α5 subunit of the GABAA receptor. The pursuit of ligands possessing only anxiolytic effects or those enhancing cognition continues to be an important focus for future research, with promising advancements depicted in recent studies.

Light-Activated Agonist-Potentiator of GABA A Receptors for Reversible Neuroinhibition in Wildtype Mice

Light-Activated Agonist-Potentiator of GABAA Receptors for Reversible Neuroinhibition in Wildtype Mice

Optogenetic Stimulation of Gaba Neurons Can Decrease Local Neuronal Activity While Increasing Cortical Blood Flow

Targeting GABAAR-Associated Proteins: New Modulators, Labels and Concepts

Optimizing GABAA receptor antagonism for the induction of long-term potentiation in the mouse and rat dentate gyrus in vitro

Discovering the Intriguing Properties of Extrasynaptic γ-Aminobutyric Acid Type A Receptors

Interrogating the function of GABAA receptors in the brain with optogenetic pharmacology

Selective Enhancement of the Interneuron Network and Gamma-Band Power via GluN2C/GluN2D NMDA Receptor Potentiation

Neuroactive Steroids and Human Recombinant Ρ1 GABA Receptors

Zolpidem Activation of Alpha 1-Containing GABAA Receptors Selectively Inhibits High Frequency Action Potential Firing of Cortical Neurons

Precisely Providing Analgesia through Selectively Targeting the GABAA {alpha}2/{alpha}3 Subtypes

The Action of Positive Allosteric Modulators of the GABAAR Can Be Reversed by Novel Spiro Barbiturates

(+/-)-( 1s, 2r, 5S)-5-amino-2-fluorocyclohex-3-enecarboxylic Acid. A Potent Gaba Aminotransferase Inactivator That Irreversibly Inhibits Via an Elimination-Aromatization Pathway

Acetylcholine receptor based chemogenetics engineered for neuronal inhibition and seizure control assessed in mice

High-efficiency optogenetic silencing with soma-targeted anion-conducting channelrhodopsins

Optogenetic determination of dynamic and cell-type-specific inhibitory reversal potentials

Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes

GluN2B Antagonism Affects Interneurons and Leads to Immediate and Persistent Changes in Synaptic Plasticity, Oscillations, and Behavior

New Insights Into Pharmacology of GABAA Receptor Alpha Subunits-Selective Modulators

Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit–Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice

Design and Synthesis of Novel Positive Allosteric Modulators of Α7 Nicotinic Acetylcholine Receptors with the Ability to Rescue Auditory Gating Deficit in Mice.